Braeburn Inc. Stock

Stocks

BBRX

US10481L1008

Pharmaceuticals

Delayed Nasdaq 5-day change 1st Jan Change
- USD -.--% Intraday chart for Braeburn Inc. -.--% -
Manager TitleAgeSince
Chief Executive Officer 58 2017-06-04
Director of Finance/CFO 55 2016-09-30
Chief Tech/Sci/R&D Officer - 2016-05-31
Director TitleAgeSince
Chairman 65 -
Director/Board Member 73 2015-08-31
Director/Board Member 55 2016-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.03%+3.00%+24.49%-6.79% 70.73B
+0.28%+2.87%+40.29%+214.73% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+7.15%+5.51%-52.67%-51.99% 39.94B
+1.76%+2.99%+61.84%-21.11% 30.36B
-2.18%+8.27%+81.16%+101.46% 25.96B
-2.36%-8.67%+60.69%-54.08% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-2.35%+1.32%+80.71%+142.71% 16.77B
Average +0.19%+1.80%+37.77%+57.54% 32.94B
Weighted average by Cap. +0.23%+2.52%+32.69%+53.25%
Logo Braeburn Inc.
Braeburn Inc is a pharmaceutical company, which focuses on the development and commercialization of long-acting medications for disorders of the central nervous system (CNS). The Company's implantable and injectable delivery mechanisms provide differentiated solutions for various diseases. The Company's therapeutic area is opioid addiction. The Company offers Probuphine. Its other therapeutic areas of focus include pain, schizophrenia and spasticity. The Company has approximately four additional late-stage product candidates in pipeline across different therapeutic areas, as well as approximately two earlier-stage product candidates. The Company's product portfolio combines approximately three primary delivery technologies with various compounds for the treatment of opioid addiction, pain, schizophrenia and spasticity: ProNeura implantable drug delivery technology, FluidCrystal injectable drug delivery platform and MedLaunch implant platform.
Employees
-
  1. Stock Market
  2. Stocks
  3. BBRX Stock